Expert Review of Anti-Infective Therapy

Scope & Guideline

Advancing the Fight Against Infectious Diseases

Introduction

Welcome to your portal for understanding Expert Review of Anti-Infective Therapy, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1478-7210
PublisherTAYLOR & FRANCIS LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2003 to 2024
AbbreviationEXPERT REV ANTI-INFE / Expert Rev. Anti-Infect. Ther.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND

Aims and Scopes

The 'Expert Review of Anti-Infective Therapy' focuses on advancing knowledge and therapies related to infectious diseases. The journal encompasses a broad range of topics, including clinical management, drug resistance, innovative treatments, and public health implications. Its multidisciplinary approach integrates insights from microbiology, pharmacology, and epidemiology to inform best practices in anti-infective therapy.
  1. Clinical Management of Infectious Diseases:
    The journal emphasizes the latest strategies and guidelines for managing various infectious diseases, particularly those caused by resistant pathogens, including detailed reviews and consensus statements from experts in the field.
  2. Emerging Therapies and Treatments:
    It covers novel therapeutic agents and innovative treatment protocols for infections, including antiviral and antifungal therapies, as well as the development of combination therapies to address multidrug-resistant infections.
  3. Antimicrobial Resistance (AMR):
    A significant focus is on understanding the mechanisms of antimicrobial resistance and exploring effective approaches to combat it, including stewardship programs and policy implications.
  4. Diagnostic Innovations:
    The journal highlights advancements in diagnostic tools and methodologies that enhance the accuracy and speed of infection detection, which is critical for timely and effective treatment.
  5. Public Health Perspectives:
    Articles often discuss the epidemiology of infectious diseases and the impact of public health policies on disease management, including the global response to outbreaks and the implications of antimicrobial use in various settings.
The journal has increasingly focused on several emerging themes, reflecting current challenges and advancements in the field of infectious diseases and anti-infective therapy.
  1. COVID-19 Treatment Innovations:
    There is a notable increase in articles addressing the treatment and management of COVID-19, including real-world data on antiviral use and the implications of COVID-19 on other infectious diseases.
  2. Antimicrobial Resistance Research:
    Research on the mechanisms, epidemiology, and management of antimicrobial resistance has gained traction, with an emphasis on innovative approaches to counteract resistance and improve treatment outcomes.
  3. Use of Artificial Intelligence in Therapy:
    Emerging studies explore the application of artificial intelligence in optimizing antibiotic prescriptions and improving diagnostic accuracy, indicating a shift towards integrating technology in infectious disease management.
  4. Personalized Medicine Approaches:
    The trend towards personalized medicine in infectious disease therapy is growing, with a focus on tailoring treatment strategies based on individual patient profiles and pathogen characteristics.
  5. Vaccine Development and Public Health Strategies:
    There is an increasing emphasis on vaccine innovation and public health strategies to prevent infectious diseases, particularly in response to emerging pathogens and outbreaks.

Declining or Waning

Over the years, certain themes within the journal have shown a decline in prominence, reflecting shifts in research focus and emerging challenges in the field of anti-infective therapy.
  1. Traditional Antifungal Therapies:
    As new antifungal agents and strategies emerge, discussions around traditional antifungal therapies have decreased, indicating a shift towards exploring more novel approaches and understanding resistance patterns.
  2. Single-Agent Antibiotic Studies:
    Research focusing solely on the efficacy of single-agent antibiotics has waned, as the emphasis shifts to combination therapies and multi-drug regimens to combat resistance.
  3. General Antibiotic Stewardship Guidelines:
    While antibiotic stewardship remains critical, there has been a decline in generic discussions, with more focus now on tailored, context-specific stewardship programs rather than broad, one-size-fits-all strategies.

Similar Journals

Indian Journal of Medical Microbiology

Connecting Global Scholars in Microbiology and Infectious Diseases
Publisher: ELSEVIERISSN: 0255-0857Frequency: 4 issues/year

Indian Journal of Medical Microbiology, published by Elsevier, is a pivotal peer-reviewed journal dedicated to the field of medical microbiology, providing a vital platform for research and scholarship since its inception in 1986. With an Open Access model established in 2001, it ensures the dissemination of scientific knowledge to a global audience, enhancing accessibility for researchers, professionals, and students alike. The journal's scope spans critical areas including immunology, infectious diseases, and microbiology, with an impressive trajectory marked by converged years of publication allowing for a comprehensive exploration of evolving scientific trends. As of 2023, the journal holds a Q3 ranking in Infectious Diseases and Microbiology (medical) and a Q4 ranking in Immunology and Microbiology categories, reflecting its significant yet growing impact in the field. Researchers seeking to contribute to or stay updated on the latest advancements in medical microbiology will find the Indian Journal of Medical Microbiology a valuable resource, as it consistently bridges the gap between emerging science and clinical application.

Current Treatment Options in Infectious Diseases

Navigating the Evolving Landscape of Infectious Disease Treatments.
Publisher: SPRINGERNATUREISSN: Frequency: 4 issues/year

Current Treatment Options in Infectious Diseases, published by SpringerNature, is a pivotal peer-reviewed journal dedicated to advancing the field of infectious disease management and therapy. With a focus on the latest treatment modalities, this journal serves as a vital resource for researchers, healthcare professionals, and students striving to improve patient outcomes in infectious diseases. Although it is not an open-access journal, it offers valuable insights through carefully curated articles that emphasize evidence-based practices and innovative approaches in the treatment landscape. By fostering a cross-disciplinary dialogue, Current Treatment Options in Infectious Diseases aims to bridge the gap between research and clinical application, making it an essential platform for staying abreast of developments in this rapidly evolving field.

MIKROBIYOLOJI BULTENI

Shaping the Future of Microbial Science
Publisher: ANKARA MICROBIOLOGY SOCISSN: 0374-9096Frequency: 4 issues/year

MIKROBIYOLOJI BULTENI, with ISSN 0374-9096, is a prestigious academic journal published by the ANKARA MICROBIOLOGY SOC, located in Ankara, Turkey. Established in 1973, this journal has been a vital conduit for disseminating research in the fields of Immunology, Microbiology, and Infectious Diseases, garnering a reputation as a significant contributor to the scientific community. The journal is currently ranked in the Q3 category within Immunology and Microbiology (miscellaneous), and Infectious Diseases, indicating its impactful presence amidst contemporary research. With access options that may be restricted, MIKROBIYOLOJI BULTENI actively welcomes submissions that advance the understanding of critical microbiological principles and practices, thereby supporting both national and international research efforts. Researchers, professionals, and students are encouraged to explore the latest findings shared in this journal, as it continually shapes the landscape of microbiology and infectious disease studies through its comprehensive and rigorous peer-reviewed publications.

Infectious Diseases and Therapy

Exploring the frontiers of infectious disease management.
Publisher: SPRINGER LONDON LTDISSN: 2193-8229Frequency: 4 issues/year

Infectious Diseases and Therapy is a premier scholarly journal published by Springer London Ltd, dedicated to advancing the understanding of infectious diseases through rigorous research and evidence-based therapy. With an esteemed Q1 ranking in both the Infectious Diseases and Microbiology (medical) categories, this journal is a vital resource for researchers, healthcare professionals, and students aiming to stay at the forefront of developments within the field. Launched in 2012, it has embraced an Open Access model, ensuring that groundbreaking studies and critical reviews are accessible to a global audience. Operating from its office in London, the journal encourages the dissemination of innovative therapies and diagnostic methods, fostering collaboration and knowledge sharing among the scientific community. In a landscape where infectious diseases pose significant health challenges, Infectious Diseases and Therapy stands as an essential platform for impactful research that can lead to improved healthcare outcomes worldwide.

GERMS

Advancing global health through innovative research.
Publisher: EUROPEAN ACAD HIV-AIDS & INFECTIOUS DISEASESISSN: 2248-2997Frequency: 4 issues/year

GERMS is a multidisciplinary journal published by the EUROPEAN ACAD HIV-AIDS & INFECTIOUS DISEASES, dedicated to advancing knowledge in the fields of epidemiology, immunology, infectious diseases, and microbiology. Since its inception in 2011, the journal has provided a crucial platform for researchers and practitioners to share innovative studies, clinical findings, and public health insights, with an eye on improving health outcomes globally. With an ISSN of 2248-2997 and a consistent publication trajectory leading up to 2024, GERMS is recognized in the third quartile across several categories, reflecting its growing impact and relevance in the scientific community. Authors and readers benefit from a range of access options, fostering the dissemination of vital research findings. As a journal situated in Romania, it also addresses regional health challenges while contributing to the broader discourse on infectious diseases and public health. GERMS is not just a repository of knowledge, but a vital resource for those engaged in combating infectious diseases and promoting health equity.

New Microbiologica

Bridging gaps in understanding with cutting-edge microbiological insights.
Publisher: EDIZIONI INT SRLISSN: 1121-7138Frequency: 4 issues/year

New Microbiologica is a prominent academic journal published by EDIZIONI INT SRL, dedicated to advancing knowledge in the fields of Microbiology and Medicine. Since its inception in 1993, this journal has played a vital role in disseminating cutting-edge research, featuring articles that explore the intricate relationships between microorganisms and human health. With an H-index indicating a robust citation profile and a respectable 2023 Scopus Ranking placing it in the 32nd percentile for medicine microbiology, New Microbiologica resonates well within the academic community. Although not an Open Access journal, it is strategically positioned in Quartile 3 of both Medicine (miscellaneous) and Medical Microbiology categories, which reflects its importance to researchers and professionals seeking valuable insights in their fields. Published in Italy, the journal continues to provide a platform for impactful research through its commitment to high-quality publications, fostering collaboration and innovation among scientists and academics in the ever-evolving landscape of microbiological studies.

Open Forum Infectious Diseases

Innovating solutions for evolving health challenges.
Publisher: OXFORD UNIV PRESS INCISSN: 2328-8957Frequency: 12 issues/year

Open Forum Infectious Diseases (ISSN: 2328-8957; E-ISSN: 2328-8957) is a leading open-access journal published by Oxford University Press, dedicated to advancing the field of infectious diseases. Since its inception in 2014, the journal has provided a platform for researchers to disseminate impactful findings in a rapidly evolving domain, achieving a remarkable Q1 ranking in both the Infectious Diseases and Oncology categories as of 2023. The journal encourages rigorous and innovative research, contributing significantly to global health discussions and informing best practices in clinical settings. As an open-access journal, it ensures that its content is accessible to a wide audience, fostering collaboration and knowledge sharing among researchers, professionals, and students alike. Positioned in the heart of the United States, Open Forum Infectious Diseases serves as a critical resource for the academic community, and its continued commitment to quality and relevance secures its status as an essential publication in the field.

Infectious Diseases

Pioneering Insights in Microbiology and Immunology
Publisher: TAYLOR & FRANCIS LTDISSN: 2374-4235Frequency: 12 issues/year

Infectious Diseases, published by TAYLOR & FRANCIS LTD, is a leading academic journal dedicated to advancing research in the field of infectious diseases and microbiology. With an impressive impact factor and categorized in Q1 in multiple areas including Immunology and Microbiology, this journal serves as a critical platform for researchers, practitioners, and students to disseminate their findings and stay abreast of current advancements. The journal is recognized for its rigorous peer-review process and aims to foster innovation and collaboration across disciplines from 2015 to 2024. It boasts a robust Scopus ranking, positioning it favorably among the top-tier of journals in the relevant fields, making it an essential resource for anyone involved in infectious disease research. Access options are available, ensuring that the latest research is accessible to a global audience, thus emphasizing the journal's commitment to promoting knowledge and understanding in the ever-evolving landscape of infectious diseases.

New Microbes and New Infections

Connecting global researchers to combat new infections.
Publisher: ELSEVIER SCI LTDISSN: Frequency: 6 issues/year

New Microbes and New Infections is an esteemed peer-reviewed journal published by Elsevier Sci Ltd that has been a prominent platform for disseminating groundbreaking research in the fields of Infectious Diseases and Microbiology since its establishment in 2013. With an impressive Open Access model, this journal ensures that vital research findings are readily accessible to researchers, healthcare professionals, and academics worldwide. Positioned in the Q2 category for Infectious Diseases and Q3 for Microbiology in 2023, it reaches a significant global audience, as demonstrated by its high Scopus rankings—#44 out of 344 in Medicine: Infectious Diseases, and #34 out of 182 in Immunology and Microbiology. The journal aims to inspire new ideas and foster collaborations by publishing high-quality research focused on novel microbes and infections, thus playing a crucial role in advancing science and public health in an era where understanding infectious agents is more vital than ever.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Empowering public health through open access research.
Publisher: ELSEVIER SCI LTDISSN: 1201-9712Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, published by ELSEVIER SCI LTD, stands as a leading platform in the realm of infectious diseases, contributing significantly to the global understanding of this critical field. With an impressive impact factor, the journal maintains a distinguished Q1 ranking across various categories, including Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology, demonstrating its high relevance and influence among contemporary research. Since its inception in 1996, it has embraced an Open Access model, allowing for wider dissemination of essential research findings that can inform public health policies and clinical practices. With a commitment to advancing scientific knowledge, this journal is not only a vital resource for researchers and professionals but also serves as an invaluable educational tool for students interested in the complexities of infectious diseases and their management. For those looking to stay at the forefront of research and innovation in this field, the INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES is an indispensable resource.